Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$50.90 USD
+0.80 (1.60%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $50.83 -0.07 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.90 USD
+0.80 (1.60%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $50.83 -0.07 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
by Zacks Equity Research
Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.
Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation
by Zacks Equity Research
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
by Zacks Equity Research
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
by Zacks Equity Research
A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Viking (VKTX) Announces Clinical Data for Metabolic Disorders
by Zacks Equity Research
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
by Zacks Equity Research
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
by Zacks Equity Research
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.
Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal
by Zacks Equity Research
Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
by Zacks Equity Research
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
Viking Therapeutics, Inc. (VKTX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
by Zacks Equity Research
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
by Zacks Equity Research
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
by Zacks Equity Research
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.
Intercept (ICPT) Announces Delay in Meeting With the FDA
by Zacks Equity Research
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
by Zacks Equity Research
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead?
by Zacks Equity Research
Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.
Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.